Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Antifungal drugs or medications are also referred as an antimycotic drugs. It is a pharmaceutical fungicide or fungistatic, which is used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis (thrush), as well as serious systemic infections such as cryptococcal meningitis, and others. Such drugs are usually obtained by a doctor's prescription, however, few are also available as OTC (over-the-counter). There are two types of antifungal drugs available in the market: local and systemic. Local antifungals are usually administered topically or vaginally, depending on the condition being treated, while systemic antifungals are administered orally or intravenously. Systemically administered drugs include ketoconazole, itraconazole, fluconazole, fosfluconazole, voriconazole, posaconazole, isavuconazole etc.

Global Antifungal Drugs Market - Impact of the Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic is expected to limit the growth of the global antifungal growth drugs market over the forecast period. The spread of the novel coronavirus has hampered growth of the healthcare industry. In December 2019, a cluster of pneumonia cases were reported by Chinese health authorities in China’s Wuhan City. The pneumonia cases’ causative agent was identified to be a novel coronavirus, which was named COVID-19. This virus spread rapidly across the globe causing a concerning number of fatalities. In March 2020, the World Health Organization (WHO) declared COVID-19 as a global pandemic and suggested implementation of strict measures to minimize the spread of this disease. The pandemic has since then slowed growth of the healthcare sector and led to a disturbance in the supply chain.

Moreover, governments across various countries have implemented nationwide lockdowns to curb the spread of COVID-19. Similarly, in various countries across the world, healthcare companies are facing problems of continuing their supply chain operations. The slowdown in the supply chain has also impacted growth of the global antifungal drugs market.

 The global antifungal drugs market is estimated to be valued at US$ 13.1 Bn in 2021 and is expected to exhibit a CAGR of 3.1% over the forecast period (2021-2028).

 Figure 1: Global Antifungal Drugs Market Share (%) Analysis, By Drug Type, 2021

Antifungal Drugs  | Coherent Market Insights

Increasing research and development activities by the market players, for the development of new products, is expected to increase the growth of the global antifungal drugs market over the forecast period.

Market players are indulged in conducting clinical trials for the development of antifungal drugs, which is expected to increase the growth of the global antifungal drugs market over the forecast period. For instance, Pfizer, Inc. is currently conducting clinical trials for determining the effectiveness, safety, and treatment patterns of isavuconazole sulfate in the treatment of patients suffering from mucormycosis or invasive aspergillosis. The trial is currently in the Phase II and is expected to be completed by May 26, 2022.

request-sample

Antifungal Drugs Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 13.1 Bn
Historical Data for: 2018 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 3.1% 2028 Value Projection: US$ 16.2 Bn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type: Echinocandins, Polyenes, Allylamines, Azoles, Others
  • By Indication: Aspergillosis, Dermatophytosis, Candidiasis, Mucormycosis, Others
  • By Dosage Form: Powders, Ointments, Drugs, thers
Companies covered:

GlaxoSmithKline Plc, Bayer AG, Abbott Laboratories, Merck & Co., Inc, Glenmark Pharmaceuticals Limited, Enzon Pharmaceuticals, Inc., Pfizer Inc., Gilead Sciences, Inc., Sanofi S.A., and Astellas Pharma, Inc.

Growth Drivers:
  • Receiving priority review status from the regulatory authorities
  • Increasing research and development activities by the market players
  • Increasing launches of antifungal drugs by the market players
  • Availability of generic antifungal drugs
Restraints & Challenges:
  • Stringent government regulations for antifungal drugs
  • Increasing drug recall rates 

Increasing product launches by the key players is expected to spur the growth of the antifungal drugs market over the forecast period.

Market players are focusing on launching new products for the treatment of antifungal infections. This is expected to increase the growth of the market over the forecast period. For instance, in 2019, Hetero Healthcare Ltd., a pharmaceutical company headquartered in Hyderabad, India, launched GOCAN I.V. Fluconazole, which is an antifungal drug for the treatment of both systemic and superficial fungal infections.

Similarly, in 2017, Pfizer Inc. launched its antifungal drug Cresemba in Spain by partnering with Basilea Pharmaceutical. The company, Pfizer Inc.  commercialized this drug in major EU markets and Austria.

Market players are focusing on launching generic products for the treatment of fungal infections, this is expected to increase the growth of the antifungal drugs market over the forecast period.

Availability of generic drugs for treatment of fungal infections is another factor that is expected to drive growth of this market. For instance, in 2016, Ajanta Pharma launched voriconazole tablets (50 mg and 200 mg dose) in the U.S market. Voriconazole tablets are the generic equivalent of Pfizer’s Vfend, an antifungal drug.

Global Antifungal Drugs Market – Restraints

Stringent government regulations are expected to restrain growth of the market. In 2020, the U.S FDA published Guidance on the approval of Antibacterial and Antifungal Drugs. According to the U.S. FDA, the Antibacterial and Antifungal Drugs will only be approved if the drug is intended to treat a serious life threatening infection in a limited population of patients with unmet needs

Additionally, increasing recall rate of pharmaceutical drugs is expected to restrain growth of this market. For instance, in August, 2020, Pharmaceutical Associates Inc. recalled around 7,416 bottles of nystatin oral suspension after the U.S Food and Drug Administration (FDA) Enforcement. The U.S. FDA designated the recall as Class II and under the recall classification, use of the affected product could cause temporary or medically reversible adverse health consequences.

Global Antifungal Drugs Market – Regional Analysis

On the basis of region, the global antifungal drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to witness significant growth in the global antifungal drugs market, owing to receiving priority review status for the antifungal drugs for the treatment of antifungal infection. For instance, on December 7, 2020, U.S. Food and Drug Administration accepted Scynexis Inc.'s application for its vaginal yeast infection drug ibrexafungerp and granted the application with priority review status. The drug also received both the qualified infectious disease product status or QIDP and fast-track designations by the U.S. FDA.

Additionally, the increasing research and development of novel antifungal medications is expected to increase the growth of the global antifungal drugs market over the forecast period. For instance, in October 2018, researchers at the American Society for Microbiology identified a compound alexidine dihydrochloride, which has a high level of antifungal and anti-biofilm activity against a diverse range of fungal pathogens, and has a potential to be considered as a pan-antifungal drug.

Figure 2: Global Antifungal Drugs Market Value (US$ Bn) & Y-o-Y Growth (%), 2020 - 2028

Antifungal Drugs  | Coherent Market Insights

Figure 3: Global Antifungal Drugs Market Share (%), by Region, 2021

Antifungal Drugs  | Coherent Market Insights

Global Antifungal Drugs Market – Competitive Landscape

Major players operating in the global antifungal drugs market include GlaxoSmithKline Plc, Bayer AG, Abbott Laboratories, Merck & Co., Inc, Glenmark Pharmaceuticals Limited, Enzon Pharmaceuticals, Inc., Pfizer Inc., Gilead Sciences, Inc., Sanofi S.A. and Astellas Pharma, Inc.    

Antifungal drugs are used to treat fungal infections in individuals. Common fungal infections such as fungal nail infection, and ringworm etc. usually occur on the external surface of the body, while certain invasive fungal infections occur inside the body tissues or inside internal organs such as lungs and brain. Fungal infection is usually associated with individuals having weak immune system, such as people suffering from HIV/AIDS. Moreover, patients undergoing chemotherapy are susceptible to invasive fungal infections. Antifungal drugs act against the fungal infections by either killing the fungal cells or by inhibiting their growth. Antifungal drugs are broadly classified as topical antifungals, oral antifungals, intravenous antifungals, and intravaginal antifungal pessaries.

Market Dynamics

Major players in the market are focused on growth strategies such as collaborations and agreements in order to enhance their market presence. For instance, in June 2017, Basilea Pharmaceutica Ltd., a biopharmaceutical company, entered into an agreement with Pfizer, Inc. and Avir Pharma, Inc. for the distribution rights of Beasilea’s antifungal treatments. Pfizer will manufacture and distribute drugs for the treatment of life-threatening invasive mold infections in regions like Russia, Israel, Europe (excluding Nordics), and Turkey.

Similarly, key players in the market are focused on various business strategies such as research and development in order to expand their product portfolio. Increasing drug development is expected to drive growth of this market. For instance, in January 2019, SCYNEXIS, Inc., a biotechnology company, announced positive interim result from their first interim efficiency analysis of an ongoing FURI study. The development of this novel treatment is indicated for antifungal treatment.

Key features of the study:

  • This report provides an in-depth analysis of global antifungal drugs market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global antifungal drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include GlaxoSmithKline Plc, Bayer AG, Abbott Laboratories, Merck & Co., Inc, Glenmark Pharmaceuticals Limited, Enzon Pharmaceuticals, Inc., Pfizer Inc., Gilead Sciences, Inc., Sanofi S.A., and Astellas Pharma, Inc.    
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global antifungal drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antifungal drugs market

Detailed Segmentation:

  • Global Antifungal Drugs Market, By Drug Type:
    • Echinocandins
    • Polyenes
    • Allylamines
    • Azoles
    • Others
  • Global Antifungal Drugs Market, By Indication:
    • Aspergillosis
    • Dermatophytosis
    • Candidiasis
    • Mucormycosis
    • Others
  • Global Antifungal Drugs Market, By Dosage Form:
    • Powders
    • Ointments
    • Drugs
    • Others
  • Global Antifungal Drugs Market, By Region:
    • North America
      • By Drug Type:
        • Echinocandins
        • Polyenes
        • Allylamines
        • Azoles
        • Others
      • By Indication:
        • Aspergillosis
        • Dermatophytosis
        • Candidiasis
        • Mucormycosis
        • Others
      • By Dosage Form:
        • Powders
        • Ointments
        • Drugs
        • Others
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Drug Type:
        • Echinocandins
        • Polyenes
        • Allylamines
        • Azoles
        • Others
      • By Indication:
        • Aspergillosis
        • Dermatophytosis
        • Candidiasis
        • Mucormycosis
        • Others
      • By Dosage Form:
        • Powders
        • Ointments
        • Drugs
        • Others
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Type:
        • Echinocandins
        • Polyenes
        • Allylamines
        • Azoles
        • Others
      • By Indication:
        • Aspergillosis
        • Dermatophytosis
        • Candidiasis
        • Mucormycosis
        • Others
      • By Dosage Form:
        • Powders
        • Ointments
        • Drugs
        • Others
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Type:
        • Echinocandins
        • Polyenes
        • Allylamines
        • Azoles
        • Others
      • By Indication:
        • Aspergillosis
        • Dermatophytosis
        • Candidiasis
        • Mucormycosis
        • Others
      • By Dosage Form:
        • Powders
        • Ointments
        • Drugs
        • Others
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • By Drug Type:
        • Echinocandins
        • Polyenes
        • Allylamines
        • Azoles
        • Others
      • By Indication:
        • Aspergillosis
        • Dermatophytosis
        • Candidiasis
        • Mucormycosis
        • Others
      • By Dosage Form:
        • Powders
        • Ointments
        • Drugs
        • Others
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Type:
        • Echinocandins
        • Polyenes
        • Allylamines
        • Azoles
        • Others
      • By Indication:
        • Aspergillosis
        • Dermatophytosis
        • Candidiasis
        • Mucormycosis
        • Others
      • By Dosage Form:
        • Powders
        • Ointments
        • Drugs
        • Others
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • GlaxoSmithKline Plc *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Bayer AG
    • Abbott Laboratories
    • Merck & Co., Inc
    • Glenmark Pharmaceuticals Limited
    • Enzon Pharmaceuticals, Inc.
    • Pfizer Inc.
    • Gilead Sciences, Inc.
    • Sanofi S.A.
    • Astellas Pharma, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Indication
      • Market Snippet, By Dosage Form
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Regulatory Scenario
    • PEST Analysis
    • Recent Product Launch/Approval
    • Epidemiology
    • Diagnosis and Treatment Overview
    • Competitive Intelligence
    • Prescription Pattern
    • Physicians Preferences and Views
  4.  Global Antifungal Drugs Market - Impact of Coronavirus (Covid-19) Pandemic
    • Impact on Supply Chain
    • Impact on Diagnosis and Treatment
    • Impact on Research and Development
  5. Global Antifungal Drugs Market, By Drug Type, 2017-2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2017 - 2028
      • Segment Trends
    • Echinocandins
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Polyenes
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Allylamines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Azoles
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  6. Global Antifungal Drugs Market, By Indication, 2017 - 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2017 - 2028
      • Segment Trends
    • Aspergillosis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Dermatophytosis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Candidiasis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Mucormycosis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  7. Global Antifungal Drugs Market, By Dosage Form, 2017 - 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2017 - 2028
      • Segment Trends
    • Powders
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Ointments
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  8. Global Antifungal Drugs Market, By Region, 2017 - 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017 - 2028
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Indication, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Dosage Form, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Type , 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Indication, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Dosage Form, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Indication, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Dosage Form, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Type , 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Indication , 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Dosage Form , 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Drug Type , 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Indication , 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Dosage Form , 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Type , 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Indication , 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Dosage Form , 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2017 - 2028 (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Company Profiles
      • GlaxoSmithKline Plc
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Bayer AG
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Merck & Co., Inc
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Enzon Pharmaceuticals, Inc.
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Pfizer Inc.
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Gilead Sciences, Inc.
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Sanofi S.A.
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Astellas Pharma, Inc.    
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
    • Analyst Views
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 34 market data tables and 28 figures on "Antifungal Drugs Market” - Global Forecast to 2028.

FAQgrowicon

Frequently Asked Questions

The global antifungal drugs market is expected to exhibit a CAGR of 3.1% during the forecast period (2021-2028).
The market is estimated to be valued at US$ 13.1 Bn in 2021.
GlaxoSmithKline Plc, Bayer AG, Abbott Laboratories, Merck & Co., Inc, Glenmark Pharmaceuticals Limited, Enzon Pharmaceuticals, Inc., Pfizer Inc., Gilead Sciences, Inc., Sanofi S.A., and Astellas Pharma, Inc. are some of the prominent players operating in the market over the forecast period.
The global antifungal drugs market is expected to be valued at US$ 16.2 Bn in 2028.
Echinocandins segment is expected to hold a major share in 2028 in the drug type.
North America is the prominent region in the market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner